Advanced

Intrajejunal Levodopa Versus Conventional Therapy in Parkinson Disease: Motor and Nonmotor Effects.

Reddy, Prashanth; Martinez-Martin, Pablo; Rizos, Alexandra; Martin, Anne; Faye, Guy C; Forgacs, Ian; Odin, Per LU ; Antonini, Angelo and Chaudhuri, K Ray (2012) In Clinical neuropharmacology 35(5). p.205-207
Abstract
ABSTRACT: Seventeen patients with advanced Parkinson disease (PD) were treated with intrajejunal L-dopa infusion (IJL) and compared with a matched group of 9 patients (termed comparator [C]) not given IJL because of funding restriction by primary care trusts (PCTs) in the UK, although considered to be clinically eligible for IJL. Assessments were baseline and follow-up (6 months) with Hoehn and Yahr staging, unified PD rating scale (UPDRS-III and UPDRS-IV), Parkinson disease questionnaire (PDQ-8, quality of life [QoL]) and nonmotor symptom scale (NMSS).Baseline characteristics were comparable between the groups. The IJL-treated group showed highly significant improvements in UPDRS-III (P = 0.005), UPDRS-IV (P = 0.0004), total NMSS score (P... (More)
ABSTRACT: Seventeen patients with advanced Parkinson disease (PD) were treated with intrajejunal L-dopa infusion (IJL) and compared with a matched group of 9 patients (termed comparator [C]) not given IJL because of funding restriction by primary care trusts (PCTs) in the UK, although considered to be clinically eligible for IJL. Assessments were baseline and follow-up (6 months) with Hoehn and Yahr staging, unified PD rating scale (UPDRS-III and UPDRS-IV), Parkinson disease questionnaire (PDQ-8, quality of life [QoL]) and nonmotor symptom scale (NMSS).Baseline characteristics were comparable between the groups. The IJL-treated group showed highly significant improvements in UPDRS-III (P = 0.005), UPDRS-IV (P = 0.0004), total NMSS score (P = 0.004), and QoL (P = 0.01), whereas the C group showed no change in these parameters. A large effect size of IJL was seen in treated patients for UPDRS-III (1.13), UPDRS-IV (1.52), NMSS score (0.82), and QoL (1.12), whereas continuing conventional treatment registered no effect in C.This study confirms the robust effect of IJL on motor and, in particular, nonmotor symptoms and QoL in advanced PD as described in open-label studies but additionally points to the need for such treatment in those denied this therapy because of centrally dictated funding policies leading to inequalities in health care. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Clinical neuropharmacology
volume
35
issue
5
pages
205 - 207
external identifiers
  • WOS:000309113300001
  • PMID:22821063
  • Scopus:84866559190
ISSN
1537-162X
DOI
10.1097/WNF.0b013e3182613dea
language
English
LU publication?
yes
id
37ff81b6-b331-4054-b657-0bd9fd9b6575 (old id 2966779)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/22821063?dopt=Abstract
date added to LUP
2012-08-09 21:21:16
date last changed
2016-10-30 04:37:25
@misc{37ff81b6-b331-4054-b657-0bd9fd9b6575,
  abstract     = {ABSTRACT: Seventeen patients with advanced Parkinson disease (PD) were treated with intrajejunal L-dopa infusion (IJL) and compared with a matched group of 9 patients (termed comparator [C]) not given IJL because of funding restriction by primary care trusts (PCTs) in the UK, although considered to be clinically eligible for IJL. Assessments were baseline and follow-up (6 months) with Hoehn and Yahr staging, unified PD rating scale (UPDRS-III and UPDRS-IV), Parkinson disease questionnaire (PDQ-8, quality of life [QoL]) and nonmotor symptom scale (NMSS).Baseline characteristics were comparable between the groups. The IJL-treated group showed highly significant improvements in UPDRS-III (P = 0.005), UPDRS-IV (P = 0.0004), total NMSS score (P = 0.004), and QoL (P = 0.01), whereas the C group showed no change in these parameters. A large effect size of IJL was seen in treated patients for UPDRS-III (1.13), UPDRS-IV (1.52), NMSS score (0.82), and QoL (1.12), whereas continuing conventional treatment registered no effect in C.This study confirms the robust effect of IJL on motor and, in particular, nonmotor symptoms and QoL in advanced PD as described in open-label studies but additionally points to the need for such treatment in those denied this therapy because of centrally dictated funding policies leading to inequalities in health care.},
  author       = {Reddy, Prashanth and Martinez-Martin, Pablo and Rizos, Alexandra and Martin, Anne and Faye, Guy C and Forgacs, Ian and Odin, Per and Antonini, Angelo and Chaudhuri, K Ray},
  issn         = {1537-162X},
  language     = {eng},
  number       = {5},
  pages        = {205--207},
  series       = {Clinical neuropharmacology},
  title        = {Intrajejunal Levodopa Versus Conventional Therapy in Parkinson Disease: Motor and Nonmotor Effects.},
  url          = {http://dx.doi.org/10.1097/WNF.0b013e3182613dea},
  volume       = {35},
  year         = {2012},
}